研究单位：[1]Foresee Pharmaceuticals Co., Ltd.[2]QPS Holdings LLC[3]Changchun GeneScience Pharmaceutical Co., Ltd.[4]Arizona University,Tucson,Arizona,United States,85719[5]Rady Children's Hospital- San Diego,San Diego,California,United States,92123[6]Nemours Children's Health Center,Jacksonville,Florida,United States,32207[7]Johns Hopkins - All Children's Hospital,Saint Petersburg,Florida,United States,33701[8]Rocky Mountain Clinical Research,Idaho Falls,Idaho,United States,83404[9]Indiana University,Indianapolis,Indiana,United States,46202[10]University of Minnesota,Minneapolis,Minnesota,United States,55454[11]University of Texas Southwestern Medical Center,Dallas,Texas,United States,75390[12]Cook Children's,Fort Worth,Texas,United States,76104[13]Multicare Health System,Tacoma,Washington,United States,98405[14]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[15]Tongji Hospital, Tongji Medical College of HUST,Wuhan,Hubei,China,430030[16]Wuhan Children's Hospital, Tongji Medical College of HUST,Wuhan,Hubei,China[17]Hunan Children's Hospital,Changsha,Hunan,China[18]Tianjin Medical University General Hospital,Tianjin,China[19]University Pediatric Hospital,San Juan,Puerto Rico,00935[20]Changhua Christian Hospital,Changhua City,Taiwan,50006[21]Mackay Memorial Hospital,Taipei City,Taiwan,104217[22]LinKou Chang-Gung Memorial Hospital (CGMH-LK),Taoyuan City,Taiwan,333423
研究目的：
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
